Gavreto (pralsetinib capsules - Blueprint Medicines) — Cigna
Non-Small Cell Lung Cancer
Initial criteria
- Patient age ≥ 18 years
- Patient has recurrent, advanced, or metastatic disease
- Patient has rearranged during transfection (RET) fusion-positive disease as detected by an approved test
Approval duration
1 year